Treatment administration
Treatment administration . | . |
---|---|
Median no. of cycles administered (range) | 7 (1-40) |
Total number of cycles administered | 400 |
Lenalidomide | |
Number of cycles administered | 400 |
Median % of targeted dose (range) | 67 (3.2-100) |
No. of patients with dose reduction (%) | 20 (57) |
Total reductions | 25 |
Reasons for reductions | |
Hematologic adverse event | 6 |
Dermatology/skin/rash | 9 |
Infection | 2 |
Other | 8 |
Cyclophosphamide | |
No. of cycles administered | 268 |
Median % of targeted dose (%) | 97 (0-108.3) |
No. of patients with dose reduction (%) | 20 (57) |
Total reductions | 28 |
Reasons for reductions | |
Hematologic adverse event | 16 |
Renal | 1 |
Infection | 3 |
Other | 8 |
Dexamethasone | |
No. of cycles administered | 384 |
Median % of targeted dose (range) | 75 (0-100) |
No. of patients with dose reduction (%) | 21 (60) |
Total reductions | 44 |
Reasons for reductions | |
Gastrointestinal | 3 |
Edema | 7 |
Weakness | 3 |
Confusion/mood alteration | 7 |
Other | 24 |
Treatment administration . | . |
---|---|
Median no. of cycles administered (range) | 7 (1-40) |
Total number of cycles administered | 400 |
Lenalidomide | |
Number of cycles administered | 400 |
Median % of targeted dose (range) | 67 (3.2-100) |
No. of patients with dose reduction (%) | 20 (57) |
Total reductions | 25 |
Reasons for reductions | |
Hematologic adverse event | 6 |
Dermatology/skin/rash | 9 |
Infection | 2 |
Other | 8 |
Cyclophosphamide | |
No. of cycles administered | 268 |
Median % of targeted dose (%) | 97 (0-108.3) |
No. of patients with dose reduction (%) | 20 (57) |
Total reductions | 28 |
Reasons for reductions | |
Hematologic adverse event | 16 |
Renal | 1 |
Infection | 3 |
Other | 8 |
Dexamethasone | |
No. of cycles administered | 384 |
Median % of targeted dose (range) | 75 (0-100) |
No. of patients with dose reduction (%) | 21 (60) |
Total reductions | 44 |
Reasons for reductions | |
Gastrointestinal | 3 |
Edema | 7 |
Weakness | 3 |
Confusion/mood alteration | 7 |
Other | 24 |